9-nitrocamptothecin liposome aerosol: Lack of subacute toxicity in dogs

被引:15
|
作者
Gilbert, BE
Seryshev, A
Knight, V
Brayton, C
机构
[1] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA
[3] Baylor Coll Med, Ctr Comparat Med, Houston, TX 77030 USA
关键词
D O I
10.1080/089583701753403980
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
9-Nitrocamptothecin (9-NC) dilauroylphosphatidylcholine (DLPC) liposome aerosol was evaluated for potential toxicity in an 8-wk, subacute toxicity study in dogs. Fourteen adult dogs were divided into 2 groups with 10 animals in the 9-NC-DLPC treatment group and 4 animals in the DLPC-only vehicle control group. 9-NC-DLPC was administered to the animals using an Aerotech II nebulizer flowing at 10 L/min. Full-face exposures for 60 min were conducted for 5 consecutive days a week for 8 wk. The estimated deposited aerosol dose was 24.7 mug/kg/day. Animals in the vehicle control group received aerosolized DLPC only. Body weight, food consumption, urinalysis, in-life observations, hematology, plasma chemistry, and necropsy and histopathology were monitored before and during the treatment period and in a subset of animals for 2 wk following the end of treatment. Animals were observed for signs of pharmacologic and/or toxicologic effects three times on days of dosing and once daily on nondosing days. 9-NC-DLPC liposomes administered as a small-particle aerosol were determined to be nontoxic to dogs when given for 5 days/wk, for a duration of 8 wk. DLPC-only liposome also had no toxic effects.
引用
收藏
页码:185 / 197
页数:13
相关论文
共 50 条
  • [41] Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin
    Gautam, A
    Waldrep, JC
    Densmore, CL
    Koshkina, N
    Melton, S
    Roberts, L
    Gilbert, B
    Knight, V
    GENE THERAPY, 2002, 9 (05) : 353 - 357
  • [42] Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin
    Rajendra, R
    Gounder, MK
    Saleem, A
    Schellens, JHM
    Ross, DD
    Bates, SE
    Sinko, P
    Rubin, EH
    CANCER RESEARCH, 2003, 63 (12) : 3228 - 3233
  • [43] PARTIAL CHARACTERIZATION OF HUMAN LEUKEMIA U-937 CELL SUBLINES RESISTANT TO 9-NITROCAMPTOTHECIN
    PANTAZIS, P
    MENDOZA, JT
    DEJESUS, A
    RUBIN, E
    KUFE, D
    GIOVANELLA, BC
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1994, 53 (03) : 135 - 144
  • [44] 9-nitrocamptothecin is an effective drug for the treatment of human lung tumors:: Comparison of in vitro and in vivo studies
    Han, ZY
    Wyche, JH
    Sands, H
    Pantazis, P
    ANTICANCER RESEARCH, 2001, 21 (3B) : 1823 - 1827
  • [45] Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma
    Ellerhorst, JA
    Bedikian, AY
    Smith, TM
    Papadopoulos, NE
    Plager, C
    Eton, O
    ANTI-CANCER DRUGS, 2002, 13 (02) : 169 - 172
  • [46] A phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors
    Michaelson, MD
    Ryan, DP
    Fuchs, CS
    Supko, JG
    Garcia-Carbonero, R
    Eder, JP
    Clark, JW
    CANCER, 2003, 97 (01) : 148 - 154
  • [47] Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin
    A Gautam
    J.C Waldrep
    C.L Densmore
    N Koshkina
    S Melton
    L Roberts
    B Gilbert
    V Knight
    Gene Therapy, 2002, 9 : 353 - 357
  • [48] 9-nitrocamptothecin selectively inhibits human immunodeficiency virus type 1 replication in freshly infected parental but not 9-nitrocamptothecin-resistant U937 monocytoid cells
    Sadaie, MR
    Doniger, J
    Hung, CL
    Pantazis, P
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (03) : 239 - 245
  • [49] SUBACUTE INHALATIONAL TOXICITY OF AEROSOL PROPELLANTS
    WATANABE, T
    AVIADO, DM
    PHARMACOLOGIST, 1975, 17 (02): : 192 - 192
  • [50] Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors
    M.J.A. de Jonge
    J.P. Droz
    L. Paz-Ares
    A.T. van Oosterom
    R. de Wit
    P. Chollet
    B. Baron
    D. Lacombe
    K. Mettinger
    P. Fumoleau
    Investigational New Drugs, 2004, 22 : 329 - 333